ADVERTISING ANALYSIS REVIEW

Source: Advertising Analysis Report, December 2004

Top Advertised Drug Classes (\$ Millions) January-December 2004

COX-2 Inhibitors		\$6.911 (-7%)
Antidepressants		\$5.673 (+11%)
Angiotensin II Antagonists	\$5	5.612 (-17%)
Anti-asthmatics/Bronchodilators	\$4.85	8 (-4%)
Ulcer Therapy	\$4.793 (+13%)	
Antibiotics	\$4.517 (+93%)	
ACE Inhibitors	\$3.513 (+3%)	
Diabetes Diagnosis & Therapy \$2	2.680 (+11%)	

Top Advertised Products January-December 2004

Crestor	\$2,54	4,000 (-21%)
Celebrex	\$2,445,000 (-8%)	
Bextra	\$2,304,000 (+2%)	
Lipitor	\$2,237,000 (-23%)	
Vioxx	\$2,162,000 (-15%	(6)
Advair	\$2,104,000 (+16%)	
Effexor XR	\$2,038,000 (-24%)	To find out more about
Altace	\$1,682,000 (-2%)	these figures, contact your STA representative.
Symbicort	\$1,577,000 (+8%)	•
Wellbutrin SR	\$1,444,000 (+999%)	John Donnet: (514) 695-8393, ext. 227 Carlo Viola: (905) 564-7700, ext. 201